1. |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021, 134(7): 783-791.
|
2. |
Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol, 2020, 38(17): 1951-1962.
|
3. |
Choong GM, Cullen GD, O’Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin, 2020, 70(5): 355-374.
|
4. |
Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol, 2021, 22(8): 1151-1161.
|
5. |
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol, 2018, 36(20): 2105-2122.
|
6. |
Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol, 2019, 11: 1758835919833519. doi:10.1177/1758835919833519.
|
7. |
刘荫华, 刘真真, 王翔, 等. 乳腺癌改良根治术专家共识及手术操作指南 (2018版). 中国实用外科杂志, 2018, 38(8): 851-854.
|
8. |
Zhang A, Wang X, Fan C, et al. The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer. Front Endocrinol (Lausanne), 2021, 12: 687244. doi: 10.3389/fendo.2021.687244.
|
9. |
Conforti F, Pala L, Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ, 2021, 375: e066381. doi: 10.1136/bmj-2021-066381.
|
10. |
Shui R, Liang X, Li X, et al. Hormone receptor and human epidermal growth factor receptor 2 detection in invasive breast carcinoma: a retrospective study of 12,467 patients from 19 Chinese Representative Clinical Centers. Clin Breast Cancer, 2020, 20(1): e65-e74.
|
11. |
Holloway RW, Marignani PA. Targeting mTOR and glycolysis in HER2-positive breast cancer. Cancers (Basel), 2021, 13(12): 2922. doi: 10.3390/cancers13122922.
|
12. |
Jin J, Tao Z, Cao J, et al. DNA damage response inhibitors: an avenue for TNBC treatment. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188521. doi: 10.1016/j.bbcan.2021.188521.
|
13. |
Manjunath M, Choudhary B. Triple-negative breast cancer: a run-through of features, classification and current therapies. Oncol Lett, 2021, 22(1): 512. doi: 10.3892/ol.2021.12773.
|
14. |
Horimoto Y, Terao T, Tsutsumi Y, et al. Estrogen receptor-positive ductal carcinoma in situ frequently overexpresses HER2 protein without gene amplification. Am J Surg Pathol, 2019, 43(9): 1221-1228.
|
15. |
胡莺菡, 吴云秋, 邓建, 等. 三阳性与HER2过表达型乳腺癌患者新辅助化学药物治疗的疗效对比. 中国普外基础与临床杂志, 2022, 29(12): 1605-1610.
|
16. |
Dehghani M, Keshavarz P, Talei A, et al. The effects of low HER2/neu expression on the clinicopathological characteristics of triple-negative breast cancer patients. Asian Pac J Cancer Prev, 2020, 21(10): 3027-3032.
|
17. |
Eggemann H, Ignatov T, Burger E, et al. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer, 2015, 22(5): 725-733.
|
18. |
Marchiò C, Annaratone L, Marques A, et al. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol, 2021, 72: 123-135.
|
19. |
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med, 2019, 380(7): 617-628.
|
20. |
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med, 2020, 382(7): 610-621.
|
21. |
Goutsouliak K, Veeraraghavan J, Sethunath V, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol, 2020, 17(4): 233-250.
|
22. |
Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol, 2019, 20(8): 1124-1135.
|
23. |
Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res, 2021, 23(1): 84. doi: 10.1186/s13058-021-01459-y.
|
24. |
Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel), 2021, 13(11): 2824. doi: 10.3390/cancers13112824.
|
25. |
Dieci MV, Miglietta F, Griguolo G, et al. Biomarkers for HER2-positive metastatic breast cancer: beyond hormone receptors. Cancer Treat Rev, 2020, 88: 102064. doi: 10.1016/ j.ctrv.2020.102064.
|
26. |
Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study. J Clin Oncol, 2020, 38(17): 1887-1896.
|
27. |
Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol, 2021, 22(6): 779-789.
|